Huang Jin-hong, Ling Chun-hua, Yang Ji-cheng, Zhao Da-guo, Xie Yu-feng, Sheng Wei-hua
Department of Respiratory, the First Affiliated Hospital of Suzhou University, Suzhou 215006, China.
Zhonghua Jie He He Hu Xi Za Zhi. 2011 Jun;34(6):413-8.
To study the radiosensitivity of the recombinant adenoviral vector (called Ad-ING4-IL-24) carrying and co-expressing inhibitor of growth 4 (ING4) and interleukin-24 (IL-24) to human lung adenocarcinoma and the underlying mechanisms.
The expression levels of ING4 and IL-24 were detected by Western blot. The growth-suppressing and apoptosis-inducing effect of Ad-ING4-IL-24 combined with radiotherapy on SPC-A-1 lung carcinoma cells were assessed by MTT assay and FCM respectively. The 25 nude mice were randomly divided into 5 groups of 5 mice ecah: PBS group, Ad group, Ad-ING4-IL-24 group, radiotherapy group and joint group (Ad-ING4-IL-24 combined radiotherapy). Mice in all groups except radiotherapy group were intratumorally injected every other day for 6 cycles. The short and long axes of the tumor were measured dynamically, tumor volume was calculated as: V = L × W(2/2), changes in tumor volume were graphed. The human lung carcinoma model was established with SPC-A-1 cells in nude mice. The ratios of tumor-suppression and q were calculated. The expression of Caspase-3, Bcl-2, Bax, VEGF in tumor samples were detected by immunohistochemistry.
The expressions of ING4 and IL-24 were successfully expressed in SPC-A-1 cells. MTT assay and FCM showed that the levels of cell-growth inhibition and apoptosis induction in Ad-ING4-IL-24 combined with radiotherapy group [(86.2 ± 0.8)%, (60.9 ± 1.0)%] were higher than in Ad-ING4-IL-24 group [(49.8 ± 0.3)%, (26.3 ± 1.3)%] and in radiotherapy group [(44.4 ± 2.2)%, (33.3 ± 0.8)%] (ratio of cell-growth inhibition, F = 550.88, P < 0.01; ratio of induced apoptosis F = 614.08, P < 0.01). Ad-ING4-IL-24 combined with radiotherapy showed an enhanced radiosensitivity effect on human lung adenocarcinoma (q = 1.20). In Ad-ING4-IL-24 group, radiotherapy group and Ad-ING4-IL-24 combined with radiotherapy group, the weight inhibition ratio was 49.5% (5 nude mice), 35.4% (5 nude mice), 79.8% (5 nude mice) respectively. Ad-ING4-IL-24 combined with radiotherapy had a synergetic and enhanced radiosensitivity effect on inhibiting the growth of transplanted tumor (q = 1.18). According to immunohistochemistry, Ad-ING4-IL-24 was shown to up-regulate the expression of Bax and Caspase-3 but down-regulate the expression of Bcl-2 and VEGF.
Ad-ING4-IL-24 had an enhanced radiosensitivity effect on human lung adenocarcinoma, and therefore acted as a radiotherapy sensitizer, which may be related to its effect on apoptosis-induction and antiangiogenesis.
研究携带并共表达生长抑制因子4(ING4)和白细胞介素-24(IL-24)的重组腺病毒载体(Ad-ING4-IL-24)对人肺腺癌的放射敏感性及其潜在机制。
采用蛋白质免疫印迹法检测ING4和IL-24的表达水平。分别采用MTT法和流式细胞术评估Ad-ING4-IL-24联合放疗对SPC-A-1肺癌细胞的生长抑制和诱导凋亡作用。将25只裸鼠随机分为5组,每组5只:PBS组、Ad组、Ad-ING4-IL-24组、放疗组和联合组(Ad-ING4-IL-24联合放疗)。除放疗组外,其余各组裸鼠每隔一天进行瘤内注射,共6个周期。动态测量肿瘤的短轴和长轴,计算肿瘤体积:V = L×W²/2,并绘制肿瘤体积变化曲线。用SPC-A-1细胞在裸鼠体内建立人肺癌模型,计算抑瘤率和增敏比(q值)。采用免疫组织化学法检测肿瘤组织中Caspase-3、Bcl-2、Bax、VEGF的表达。
ING4和IL-24在SPC-A-1细胞中成功表达。MTT法和流式细胞术检测结果显示,Ad-ING4-IL-24联合放疗组细胞生长抑制率[(86.2±0.8)%]和诱导凋亡率[(60.9±1.0)%]高于Ad-ING4-IL-24组[(49.8±0.3)%,(26.3±1.3)%]和放疗组[(44.4±2.2)%,(33.3±0.8)%](细胞生长抑制率,F = 550.88,P < 0.01;诱导凋亡率,F = 614.08,P < 0.01)。Ad-ING4-IL-24联合放疗对人肺腺癌具有增敏作用(q = 1.20)。Ad-ING4-IL-24组、放疗组和Ad-ING4-IL-24联合放疗组的体重抑制率分别为49.5%(5只裸鼠)、35.4%(5只裸鼠)、79.8%(5只裸鼠)。Ad-ING4-IL-24联合放疗对移植瘤生长抑制具有协同增敏作用(q = 1.18)。免疫组织化学结果显示,Ad-ING4-IL-24可上调Bax和Caspase-3的表达,但下调Bcl-2和VEGF的表达。
Ad-ING4-IL-24对人肺腺癌具有增敏作用,可作为放疗增敏剂,其机制可能与诱导凋亡和抗血管生成作用有关。